|[August 06, 2014]
Provectus Biopharmaceuticals Inc. to Commence Series of Quarterly Conference Calls on Thursday, August 7, 2014
KNOXVILLE, Tenn. --(Business Wire)--
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) (http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company,
will begin a series of regular quarterly conference calls to update the
market in general and shareholders in particular about developments at
the Company. In the future, these calls will coincide with the filing of
the Company's 10-Q and 10-K filings with the Securities and Exchange
Commission as appropriate.
Craig Dees, PhD, CEO of Provectus, said, "As part of our drive for
greater transparency, we have decided to hold conference calls to
coincide with the filing of our 10-Q and 10-Ks with the SEC (News - Alert). If there is
a material development in the future that warrants immediate discussion,
we will naturally hold a special conference call rather than wait for
the quarterly call."
Conference Call Thursday, August 7, 2014, at 4:00 PM EDT
The management of Provectus Biopharmaceuticals, Inc. will host a
conference call on Thursday, August 7, 2014 at 4:00 PM Eastern. Those
who wish to participate in the conference call may telephone
877-407-4019 from the U.S. International callers may telephone
201-689-8337, approximately 15 minutes before the call. A webcast will
also be available at: www.pvct.com.
A digital replay will be available by telephone approximately two hours
after the completion of the call until August 31, 2014, and may be
accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for
international callers, and using the Conference ID#13588317.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and
dermatology therapies. PV-10, its novel investigational drug for cancer,
is designed for injection into solid tumors (intralesional
administration), thereby reducing potential for systemic side effects.
Its oncology focus is on melanoma, breast cancer and cancers of the
liver. The Company has received orphan drug designations from the FDA
for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has recently
completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma,
and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Information about these and the Company's other clinical trials can be
found at the NIH registry,www.clinicaltrials.gov.
For additional information about Provectus please visit the Company's
website at www.pvct.com or
contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking
statements" as defined under U.S. federal securities laws. These
statements reflect management's current knowledge, assumptions, beliefs,
estimates, and expectations and express management's current views of
future performance, results, and trends and may be identified by their
use of terms such as "anticipate," "believe," "could," "estimate,"
"expect," "intend," "may," "plan," "predict," "project," "will," and
other similar terms. Forward-looking statements are subject to a number
of risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking
statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking statements
include those discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on
Form 10-K for the year ended December 31, 2013, and in our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2014), and the
our determination, based on guidance from the FDA, whether to
proceed with or without a partner with a phase 3 trial of PV-10 to
treat locally advanced cutaneous melanoma and the costs associated
with such a trial if it is necessary;
our determination whether to license PV-10, our melanoma drug
product candidate, and other solid tumors such as liver cancer, if
such licensure is appropriate considering the timing and structure
of such a license, or to commercialize PV-10 on our own to treat
melanoma and other solid tumors such as liver cancer;
our ability to license our dermatology drug product candidate,
PH-10, on the basis of our phase 2 atopic dermatitis and psoriasis
results, which are in the process of being further developed in
conjunction with mechanism of action studies; and
our ability to raise additional capital if we determine to
commercialize PV-10 and/or PH-10 on our own, although our
expectation is to be acquired by a prospective pharmaceutical or
biotech concern prior to commercialization.
[ Back To TMCnet.com's Homepage ]